Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Cheng AL, Cornelio G, Shen L, Price T, Yang TS, Chung IJ, Dai GH, Lin JK, Sharma A, Yeh KH, Ma B, Guan Z, Masood N, Srimuninnimit V, Chatterjee S, Gorospe C, Doval DC, Shim BY

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Leyland-Jones B, Bondarenko I, Nemsadze G, Smirnov V, Litvin I, Kokhreidze I, Abshilava L, Janjalia M, Lakshmaiah KC, Tarasova O, Mohapatra RK, Sparyk Y, Polenkov S, Vladimirov V

Adrenocortical carcinoma presenting as subclinical hypercortisolism in a young adult female: A case report

Mary Grace Astudillo. MD

Adrenocortical carcinoma is a rare adrenal malignancy which may present with symptoms similar to Cushing’s syndrome and flank pain.

Multiple myeloma presenting as left-sided weakness: a case report

Cristina Domingo

Left-sided weakness, as well as other neurologic symptoms, from multiple myeloma happens only in 5% of cases.

Persistent hyperbilirubinemia in a B Cell Non-Hodgkin’s lymphoma: a case of suspected paraneoplastic cholestasis

Lordan Carreon. MD

Lymphoma can sometimes infiltrate the liver and cause persistent bilirubinemia. A liver biopsy may be warranted to exclude the diagnosis.

Validity study of clinical scoring systems to predict Hepatocellular Carcinoma among chronic Hepatitis B carriers at St. Lukes Medical Center-Global City

Ian Homer Cua. MD, Macky Gregor Bautista. MD, Namphril Malaluan. MD, Lee Roi Buenaventura. MD

Chronic hepatitis B is the leading cause of cirrhosis and hepatocellular carcinoma in Asia. However, only a proportion of patients with chronic infection of hepatitis B virus will develop hepatocellular carcinoma. Stratifying patients with hepatitis B who are more likely to develop hepatocellular carcinoma will help to direct efforts of early interventions and more rigorous surveillance.

A Meta-Analysis on the Efficacy a Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) Versus Palonosetron (PALO) Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Emetogenic Chemotherapy

Ian Homer Cua. MD, Enrik Aguila. MD, Kristine Reyes, Anne Kimberly Lim. MD

Nausea and vomiting are among the most common adverse effects of emotegenic chemotherapy and, if not prevented or controlled, may lead to deleterious effects to patients, noncompliance to treatment and poor quality of life. Hence, new drugs are currently being studied to give the most favorable response for cancer patients receiving emetogenic chemotherapeutic drugs. NEPA, a combination drug of Netupitant (NETU) and Palonosetron (PALO), is the first combination oral agent ...

Review of Recurrent Glioma Patients Treated with Reirradiation and Chemotherapy

Angela Gaerlan, Julette Marie Batara, Miriam Joy Calaguas, Dan Joseph Manlapaz, Paul Vincent Opinaldo. M.D, Julius Cezar Rojales. BSc, Dan Joseph Manlapaz. BSc

Surgical resection followed by radiotherapy with temozolomide for patients with newly diagnosed Glioblastoma Multiforme (GBM) has shown a significant prolongation of survival and is now the standard of care. However, at present, no standard of treatment has been defined for recurrence.